Payment overview · 2025
General Payments
$416.80
8 reported records · 5 companies
Healthcare provider profile · identity verified
Jaime Holberton Square, M.D.
Allopathic & Osteopathic Physicians|General Practice · EL PASO, TX · NPI 1205046752
Verified facts
What the public records show
CMS Open Payments records show Jaime Holberton Square, M.D. received $416.80 in general payments during 2025 across 8 reported records.
REVANCE THERAPEUTICS, INC. accounted for 79.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $332.38 | 79.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.45 | 5.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.34 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.97 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.66 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.80 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $279.25 | 3 | 2025 |
Source payment records
|
|||||
| DAXI Normalized: daxi |
Drug | REVANCE THERAPEUTICS, INC. | $53.13 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 381 | 97 |
| Metformin Hcl | Metformin Hcl | 316 | 92 |
| Lisinopril | Lisinopril | 288 | 74 |
| Gabapentin | Gabapentin | 258 | 54 |
| Losartan Potassium | Losartan Potassium | 230 | 69 |
| Eliquis | Apixaban | 229 | 39 |
| Furosemide | Furosemide | 207 | 49 |
| Memantine Hcl | Memantine Hcl | 185 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 47 |
| Simvastatin | Simvastatin | 156 | 43 |
| Lactulose | Lactulose | 153 | 34 |
| Trazodone Hcl | Trazodone Hcl | 149 | 42 |
| Montelukast Sodium | Montelukast Sodium | 143 | 49 |
| Sertraline Hcl | Sertraline Hcl | 138 | 26 |
| Omeprazole | Omeprazole | 133 | 51 |
| Buspirone Hcl | Buspirone Hcl | 125 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 47 |
| Tramadol Hcl | Tramadol Hcl | 121 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 33 |
| Januvia | Sitagliptin Phosphate | 111 | 20 |
| Donepezil Hcl | Donepezil Hcl | 109 | 21 |
| Carvedilol | Carvedilol | 107 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 25 |
| Ozempic | Semaglutide | 99 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 94 | 38 |
| Mirtazapine | Mirtazapine | 94 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 24 |
| Potassium Chloride | Potassium Chloride | 82 | 15 |
| Sucralfate | Sucralfate | 79 | 29 |
| Alendronate Sodium | Alendronate Sodium | 73 | 25 |
| Alprazolam | Alprazolam | 71 | 16 |
| Allopurinol | Allopurinol | 70 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 19 |
| Levetiracetam | Levetiracetam | 64 | 13 |
| Famotidine | Famotidine | 63 | 17 |
| Prednisone | Prednisone | 62 | 38 |
| Ibuprofen | Ibuprofen | 60 | 27 |
| Meloxicam | Meloxicam | 60 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 58 | suppressed |
| Finasteride | Finasteride | 51 | 17 |
| Clonazepam | Clonazepam | 50 | 13 |
| Azithromycin | Azithromycin | 49 | 47 |
| Cefuroxime | Cefuroxime Axetil | 49 | 45 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Pregabalin | Pregabalin | 48 | 14 |
| Ramelteon | Ramelteon | 44 | 23 |
| Naproxen | Naproxen | 43 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 25 |
| Farxiga | Dapagliflozin Propanediol | 39 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 12 |
| Gemtesa | Vibegron | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 20 |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 19 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 15 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 22 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Baclofen | Baclofen | 28 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 12 |
| Torsemide | Torsemide | 27 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 12 |
| Atenolol | Atenolol | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 11 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 15 |
| Glipizide | Glipizide | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 11 |
| Temazepam | Temazepam | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.80 · 8 records | REVANCE THERAPEUTICS, INC. | ABRYSVO, COMIRNATY, DAXI, DAXXIFY, FREESTYLE LIBRE 3, Kerendia, Korlym, PREVNAR 20 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error